aTyr Pharma ATYR Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$10.79M+22.7% | -$13.96M+45.8% | -$25.75M-31.8% | -$19.53M-31.3% | -$14.88M+0.6% | ||
| $162K-2.4% | $166K+0.6% | $165K-0.6% | $166K-0.6% | $167K-4.6% | ||
| $1.31M+8.3% | $1.21M-7.7% | $1.31M+0.2% | $1.31M+10.8% | $1.18M+53.0% | ||
| -$3.47M-547% | -$536K-3,078% | $18K-99.6% | $4.81M+211% | -$4.32M— | ||
| -$91K+91.7% | -$1.09M+77.2% | -$4.8M— | $0+100% | -$2.16M— | ||
| $232K+1.8% | $228K+1.8% | $224K+1.4% | $221K+2.3% | $216K— | ||
| -$191K-2.1% | -$187K-2.2% | -$183K-2.2% | -$179K-10.5% | -$162K— | ||
| -$396K-134% | -$169K— | —— | -$490K+34.5% | -$748K-687% | ||
| -$12.52M-2.6% | -$12.2M+40.4% | -$20.48M-47.4% | -$13.89M+9.9% | -$15.42M-17.4% | ||
| $138K+345% | $31K-16.2% | $37K+311% | $9K— | $0-100% | ||
| $5.87M-54.3% | $12.85M-67.3% | $39.34M+117% | $18.16M-21.4% | $23.11M-11.4% | ||
| $17.5M-40.3% | $29.31M+54.2% | $19M-11.5% | $21.47M+14.9% | $18.69M-6.6% | ||
| $11.49M— | —— | -$20.38M— | —— | -$4.42M— | ||
| $0— | —— | —— | $17K+750% | $2K— | ||
| $142K+2.2% | $139K+2.2% | $136K+2.3% | $133K+1.5% | $131K+2.3% | ||
| -$142K— | $0-100% | $29.62M+65.5% | $17.9M-3.9% | $18.63M-1.1% | ||
| -$1.17M— | —— | -$11.24M-254% | $7.3M+703% | -$1.21M-221% | ||
| $17K-10.5% | $19K-13.6% | $22K-12.0% | $25K-10.7% | $28K-6.7% | ||
| $255K-29.4% | $361K-29.5% | $512K+11.8% | $458K-12.4% | $523K-4.9% | ||
| $1.31M+8.3% | $1.21M-7.7% | $1.31M+0.2% | $1.31M+10.8% | $1.18M+53.0% | ||
| -$191K-2.1% | -$187K-2.2% | -$183K-2.2% | -$179K-10.5% | -$162K— | ||
| -$396K-134% | -$169K— | —— | -$490K+34.5% | -$748K-687% | ||
| -$91K+91.7% | -$1.09M+77.2% | -$4.8M— | $0+100% | -$2.16M— | ||
| $232K+1.8% | $228K+1.8% | $224K+1.4% | $221K+2.3% | $216K— | ||
| $17.5M-40.3% | $29.31M+54.2% | $19M-11.5% | $21.47M+14.9% | $18.69M-6.6% | ||
| $142K+2.2% | $139K+2.2% | $136K+2.3% | $133K+1.5% | $131K+2.3% | ||
| $0— | $0-100% | $29.75M+65.9% | $17.93M-4.4% | $18.76M-0.8% | ||
| $0— | —— | —— | $17K+750% | $2K— | ||
| -$191K-2.1% | -$187K-2.2% | -$183K-2.2% | -$179K-10.5% | -$162K— | ||
| —— | $0— | $0— | $0— | $0— | ||
| $15K— | —— | $31K— | —— | $17K— | ||
| -$12.66M-3.5% | -$12.23M+40.4% | -$20.51M-47.5% | -$13.9M+9.8% | -$15.42M-17.2% | ||
| -$12.66M-3.5% | -$12.23M+40.4% | -$20.51M-47.5% | -$13.9M+9.8% | -$15.42M-17.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does aTyr Pharma generate?
- aTyr Pharma (ATYR) generated -$59.1M in operating cash flow over the trailing twelve months.
- What is aTyr Pharma's free cash flow?
- After $215.0K of capital expenditures, aTyr Pharma's free cash flow was -$59.3M over the trailing twelve months, up 4.7% year over year.
- Where does aTyr Pharma's cash flow data come from?
- Every line is extracted from aTyr Pharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
